Inclusion Criteria:

- Participants aged 18 to 55 years (Cohort A and C), aged 56 to 69 years (Subcohorts B1
and D1), or aged ≥ 70 years (Subcohorts B2 and D2)

Exclusion Criteria:

1. Known past laboratory-confirmed SARS-CoV-2 infection

2. Positive SARS-CoV-2 RT PCR test at screening

3. Seropositivity to SARS-CoV-2 at screening.

4. Significant infection or other illness, including fever > 37.8°C on the day prior to
or day randomization

5. History of Guillain-Barré syndrome

6. Any confirmed or suspected immunosuppressive or immunodeficient state; asplenia;
recurrent severe infections and use of immunosuppressant medication within the past 6
months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days)

7. History of allergy to any component of the vaccine

8. Any history of angioedema

9. Any history of anaphylaxis

10. Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin
and uterine cervical carcinoma in situ)

11. History of serious psychiatric condition likely to affect participation in the study

12. Bleeding disorder (eg, factor deficiency, coagulopathy or platelet disorder), or prior
history of significant bleeding or bruising following IM injections or venepuncture

13. Suspected or known current alcohol or drug dependency

14. Any other significant disease, disorder or finding which may significantly increase
the risk to the participant because of participation in the study, affect the ability
of the participant to participate in the study or impair interpretation of the study
data

15. Severe and/or uncontrolled cardiovascular disease, respiratory disease,
gastrointestinal disease, liver disease, renal disease, endocrine disorder and
neurological illness (mild/moderate well controlled comorbidities are allowed)